- Peptide (C)ETFRDKLRLYVAQK, corresponding to amino acid residues 329-342 of rat GPER (Accession O08878). Intracellular, C-terminus.
- Western blot analysis of rat brain (lanes 1 and 4), mouse brain (lanes 2 and 5) and rat lung (lanes 3 and 6):1-3. Anti-GPER (GPR30) Antibody (#AER-050), (1:200).
4-6. Anti-GPER (GPR30) Antibody, preincubated with GPER/GPR30 Blocking Peptide (#BLP-ER050).
- Expression of GPER in rat dentate gyrusImmunohistochemical staining of rat hippocampal dentate gyrus using Anti-GPER (GPR30) Antibody (#AER-050). A. GPER staining (green) appears in cells and fibers of the hilus (arrows) and granule layer (G) B. Parvalbumin (red) is detected in cells in the DG hilus (arrows). C. Nuclei staining using DAPI as the counterstain (blue). D. Merge image of panels A and B reveals colocalization in some cells (arrows).
The G protein-coupled estrogen receptor (GPER), formerly known as G protein receptor 30 (GPR30), was identified as a novel estrogen receptor that mediates a rapid, non-genomic response to estrogens1.
GPER is a G protein-coupled seven-transmembrane receptor. It is believed that the N-terminus is located outside of the cell, and that aspartic acid residues in the terminal region might be modified by glycosylation if GPER is localized in the plasma membrane. It is speculated that the ligand associates with the N-terminal domain to activate the receptor. Trimeric G protein is presumed to bind to the 3rd loop of the intracellular domain based on the molecular structure. A PDZ domain appears to be in the C-terminal region of GPER, but its physiological role is unknown2.
GPER is widely distributed in the human body including: brain, liver, heart, lung, pancreas, placenta, blood vessels, bone, lymphoid tissue, as well as endometrial, ovarian and breast cancer. The receptor has been localized both in the plasma membrane and in the endoplasmic reticulum3.
It was found that GPER is rapidly induced in the cardiomyocyte ischemia model, and that its induction is associated with apoptotic cell death during ischemia and reperfusion4. In addition, the GPER mediates estrogenic signaling in breast cancer cells and cancer-associated fibroblasts (CAF) that contribute to cancer progression5.
Species reactivity key:
Anti-GPER (GPR30) Antibody (#AER-050) is a highly specific antibody directed against an epitope of rat G-protein coupled estrogen receptor 1. The antibody can be used in western blot and immunohistochemistry applications. It has been designed to recognize GPER from rat, mouse and human samples.
- Anti-GPER1/GPR30 (extracellular) Antibody (#AER-049). This antibody recognizes a different epitope and thus can also be used as a control for detecting GPR30.
- Anti-GPER1/GPR30 (extracellular)-FITC Antibody (#AER-049-F). This FITC-conjugated antibody can be used to detect GPER1 in live cell flow cytometry.